The High Supreme Committee for Registration of Pharmaceutical Companies and Products within the Libyan Ministry of Health approved Ursapharm’s registration and issued the registration certificate of manufacturing site and company registration. This registration process included a 2-day onsite visit of Ursapharm’s Manufacturing site in Saarbruken Germany by the Libyan committee’s inspectors accompanied by Wadi Zen’s CEO Rafik Shenib and Prohealth’s Executive Director Andrew Paris.
” I am pleased to have led this registration process, bringing together the requests of the Libyan Health Authorities and the expertise of the Regulatory Team at Ursapharm in Germany. Together with our Libyan partners we have managed to overcome the obstacles provided by the Covid pandemic and other challenges to become one of the first European Market Authorisation Holders (MAHs) to be successfully audited by the Libyan Health Authorities. We hope that this experience will also allow us to undertake similar inspections and registration procedures with other European MAHs for the Libyan market” – Andrew Paris, Executive Director.